This study will use PET neuroimaging to determine the amount of tau protein in the brain and to explore the relationship between presence of tau and clinical course of Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
This trial will study the efficacy and tolerability of drugs targeting Alzheimer's disease in patients with a genetic predisposition to the disease.
This telephone support intervention aims to help caregivers by providing them with the support and strategies they need to manage challenging behaviors.
This study examines the progression and symptoms of primary progressive aphasia (PPA) and differentiates subtypes of PPA.
This study examines how the proteins tau and amyloid affect brain regions and relate to symptoms of typical and atypical Alzheimer's disease (AD).
This survey aims to help researchers better understand how the experience of caregiving affects mental health and wellbeing.
The goal of the study is to obtain a uniform set of data from individuals who have various types of dementia (e.g., Alzheimer’s disease, frontotemporal degeneration, lewy body dementia, etc..) and from healthy older individuals in order to understand how dementia (a decline in mental ability) develops in the human brain.
The purpose of the ADNI-3 study is to create a national database of brain aging from volunteers age 55 - 90, to improve clinical trials and provide researchers across the country with data to study how quickly brain cognition and function changes. This study is funded by the National Institutes of Health.
Healthy, normal volunteers needed for a study of brain protein deposits that commonly occur with normal aging. This study involves 4 PET scans, 1 MRI scan, and cognitive testing. The scans are 30-120 minutes in length and the cognitive testing can last up to 2 hours.
Are you between the ages of 70 and 90 and have depressive symptoms? This observational study is being carried out to determine whether the presence or absence of late onset depressive symptoms in older adults predicts more rapid Alzheimer’s Disease (AD) associated brain related changes and AD associated cognitive decline.